The future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how. Backed by True Ventures.
About the role
We are seeking a highly capable and proactive Scientist / Senior Scientist, tLNP Formulation and Delivery to join our Boston, MA team. This role reports to the Head of Gene Editing and Early Discovery and owns the end-to-end design, formulation, bioconjugation, and physicochemical characterization of novel targeted lipid nanoparticles (tLNPs). Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- LNP assembly & bioconjugation: Hands-on experience with LNP assembly platforms (microfluidic/NanoAssemblr, T mixing, or ethanol injection) and surface bioconjugation techniques to functionalize nanoparticles with targeting moieties
- Tropism engineering: Demonstrated understanding and experience in shifting nanoparticle biodistribution/tropism through lipid compositional tweaking, molar ratio modification, or structural lipid alteration
- LNP analytical techniques: Experience with LNP analytical techniques such as DLS, encapsulation assays, etc
- Hands-on LNP experience: Hands-on experience with targeted LNPs or LNPs and conjugation of biomaterials
- High-Throughput Screening: Experience with automated or high-throughput liquid-handling platforms for formulation screening
- DoE Software: Practical knowledge of Design of Experiments (DoE) software (e.g., JMP) for systematic LNP optimization
More about this role
Basecamp Research is building frontier AI for therapeutic design. We believe the future of medicine lies in reprogramming the body to repair itself, and we design the models and the medicines to teach it how.
Our EDEN models are trained on BaseData, the world's largest proprietary genomic dataset, with over 10B genes collected through partnerships in more than 30 countries across all seven continents. This gives our AI models access to genetic diversity that doesn't exist in public databases, and enables EDEN to design cell and gene therapies, enzymes, and peptides directly from information about a disease. Our pipeline of EDEN-designed therapeutics, beginning with in vivo cell therapy, is advancing towards clinical development.
In September 2026 we closed an oversubscribed $140M Series C led by S32, with participation from NVIDIA, Anthropic's Anthology Fund, Catalio, European Tech Collective, Firebrand River Capital, King Philanthropies, NATO Innovation Fund, NVentures (NVIDIA's venture arm), Redalpine, Rockefeller Foundation, Singular, Sovereign AI and True Ventures. We have offices and labs in London and Boston, we partner with biopharma companies and academic institutions...
Browse similar: Startup jobs